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Abstract
Aims/hypothesis We sought to establish the relationship
betweenfasting plasmaglucose concentrationsand pancreatic
fractional beta cell area in adult cynomolgus monkeys
(Macaca fascicularis).
Methods Fasting plasma glucose and pancreatic fractional
beta cell area were measured in 18 control and 17
streptozotocin-treated adult primates (17.0±1.2 vs 15.4±
1.2 years old).
Results Fasting plasma glucose was increased (12.0±2.0 vs
3.4±0.1 mmol/l, p<0.01) and fractional beta cell area was
decreased (0.62±0.13% vs 2.49±0.35%, p<0.01) in
streptozotocin-treated monkeys. The relationship between
fasting plasma glucose and pancreatic fractional beta cell
area was described by a wide range of beta cell areas in
controls. In streptozotocin-treated monkeys there was an
inflection of fasting blood glucose at ∼50% of the mean
beta cell area in controls with a steep increase in blood
glucose for each further decrement in beta cell area.
Conclusions/interpretation In adult non-human primates a
decrement in fractional beta cell area of ∼50% or more
leads to loss of glycaemic control.
Keywords Betacellmass.Cynomolgusmonkey.
Streptozotocin.Type1diabetes.Type2diabetes
Abbreviations
FPG Fasting plasma glucose
STZ Streptozotocin
Introduction
In health, the blood glucose concentration is regulated by
insulin secreted by pancreatic beta cells. Diabetes arises
when insufficient insulin is secreted to maintain glycaemic
control. In type 1 and type 2 diabetes this is at least in part
due to a deficit in beta cell mass [1–3]. There is
inconsistency in the published literature as to what
constitutes sufficient beta cell mass to sustain glycaemic
control. The surgical literature has suggested as much as an
80% pancreatic resection can be tolerated without diabetes
[4, 5]. However, more comprehensive metabolic studies of
humans and dogs after a partial pancreatectomy have
suggested that ∼50% pancreatectomy results in impaired
fasting glucose and glucose intolerance in the short term [6]
and diabetes in some individuals over the next few years
[7, 8].
The latter data are consistent with cross-sectional studies
of the relationship between fasting blood glucose concen-
tration and pancreatic fractional area in humans [3]. In
obese individuals, this relationship is curvilinear, with an
inflection of blood glucose with a deficit of ∼50% or more
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another study of dogs it was suggested that insulin secretion
was minimally effected with an ∼50% pancreatic resection
[9].
Here we report the relationship between fasting plasma
glucose (FPG) and fractional pancreatic beta cell area in
adult cynomolgus monkeys (Macaca fascicularis).
Methods
Animals A total of 35 male cynomolgus monkeys (Macaca
fascicularis, age: 16.2±0.9 years, range 5 to 27 years; body
weight: 5.8±0.3 kg, range 3.4 to 9.8 kg) were studied.
Monkeys were originally imported from Institut Pertanian
(Bogar, Indonesia) and were pair-housed at the Compara-
tive Medicine Clinical Research Center at Wake Forest
University School of Medicine, Winston-Salem, NC, USA.
Among them, 18 monkeys (nine control and nine strepto-
zotocin [STZ]-treated monkeys) had been included in a
previous study reported elsewhere [10]. Monkeys were
randomly assigned to either the control (n=18) or the STZ
(n = 17) group. Control and STZ groups were matched for
age (17.0±1.2 vs 15.4±1.2 years, p=0.3) and body weight
(6.1±0.4 vs 5.6±0.3 kg, p=0.3). All procedures involving
animals were conducted in compliance with state and
federal laws, standards of the US Department of Health
and Human Services, and guidelines established by the
Wake Forest University Institutional Animal Care and Use
Committee.
Induction of diabetes To induce diabetes, freshly prepared
STZ (Zanosar; SICOR Pharmaceuticals, Irvine, CA, USA)
was given intravenously in a single bolus (30 mg/kg) to
monkeys in the STZ group. To monitor the effect of STZ,
the fasting blood glucose concentration was measured on
alternate days for a week, (Accu-Check Glucose Monitor;
Boehringer Mannheim, Indianapolis, IN, USA). Of the 17
monkeys in the STZ group, six required a second STZ
injection 1 week after the first and three monkeys required a
third STZ injection 1 week after the second to induce
diabetes. The criterion for diabetes was a fasting blood
glucose>8 mmol/l 48 h post STZ injection. To avoid
ketosis in hyperglycaemic monkeys, insulin therapy (Novo-
lin 70/30; Novo Nordisk USA, Princeton, NJ, USA) was
started at a dosage of 0.4 U/kg twice daily and then the
dose was gradually increased to a target fasting blood
glucose concentration of 8 to 14 mmol/l.
Fasting blood samples were collected under ketamine
sedation 4 weeks (nine control and nine STZ monkeys) or
14 weeks (nine control and eight STZ monkeys) after the
STZ (or saline) injection. To avoid the effect of exogenous
insulin, monkeys were treated with the same dose of regular
insulin (Novolin R; Novo Nordisk USA) instead of Novolin
70/30 on the evening prior to blood sampling. Plasma
glucose concentration was determined by the glucose
oxidase method by using a Glucose Analyzer 2 (Beckman
Instruments, Brea, CA, USA).
Tissue collection After collectionofthebloodsamples (i.e.4
or 14 weeks after the STZ [or saline] treatment), the animals
were killed by overdose with intravenous pentobarbital, and
the pancreases were harvested intact, immediately weighed,
cut into 3–4 mm sections and fixed in ice-cold neutral-
buffered 10% (vol./vol.) formalin for 24 h. The pancreases
were then transferred into 70% (vol./vol.) alcohol for another
24 h at 4°C prior to processing and embedding in paraffin for
the subsequent procedure.
Morphometric analysis For immunohistochemistry, 4 µm
sections of pancreas containing a minimum of 100 islets were
stained with guinea pig anti-insulin antibody, 1:100 (Zymed
Laboratories, San Francisco, CA, USA) and haematoxylin.
Then the entire pancreatic section stained for insulin was
imaged at ×40 magnification (×4 objective). The ratio of the
beta cell area/total pancreas parenchymal area was digitally
quantifiedusingImageProPlussoftware(MediaCybernetics,
Silver Springs, MD, USA) as previously described [2].
Statistical analysis Data are presented as mean ± SEM. The
Student’s t test was used for comparisons. The relation
between the fasting plasma glucose (y in mmol/l) and the
beta cell area (x in %) was described with the model
Fig. 1 Curvilinear relationship between the percentage of pancreas
occupied by beta cells and fasting plasma glucose in cynomolgus
monkeys. Circles, control monkeys; triangles, STZ-treated monkeys.
The solid line is derived from non-linear regression analysis (r
2=0.59;
p<0.0001). The dashed vertical lines indicate the mean fractional
pancreatic beta cell area in the control group (2.5%, right) and ∼50%
of that value (1.3%, left)
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decay plus plateau:
y ¼ plateau þ span   e k x ð1Þ
where plateau (mmol/l) was the FPG value related to
elevated beta cell areas, span (mmol/l) was the increase
above plateau corresponding to a beta cell area equal to
zero, and k (%
−1) was the constant rate of the mono-
exponential function.
Model variables (i.e. plateau, span and k) were estimated,
together with a measure of their precision (coefficient of
variation), by non-linear least squares [11]u s i n gS A A MI I
software [12].
Results
As expected, the fasting plasma glucose concentrations
measured shortly before death and necropsy were higher in
STZ-treated diabetic monkeys compared with control
monkeys (12.0±2.0 vs 3.4±0.1 mmol/l, p<0.01). Also,
the pancreatic fractional beta cell area was decreased in
STZ-treated diabetic monkeys compared with control
monkeys (0.62±0.13% vs 2.49±0.35%, p<0.01).
The relationship between the fasting plasma glucose
concentration and the pancreatic fractional insulin area was
well described by the mono-exponential model relationship
in equation 1 (Fig. 1). The model variables were estimated
with good precision: plateau=3.5±1.3 mmol/l (CV 37%),
span=19.4±3.1 mmol/l (CV 16%), k=2.3±0.7 %
−1 (CV
33%). There was a wide range of fractional beta cell areas in
control monkeys. Blood glucose concentrations increased
steeply once the pancreatic fractional beta cell area decreased
to 50% or less that of the mean of that in control monkeys.
Discussion
We report that the relationship between the pancreatic
fractional beta cell area and the fasting plasma glucose
concentration in cynomolgus monkeys is reminiscent of
that in humans with and without type 2 diabetes [3]. The
relationship is also comparable with that observed previ-
ously in a porcine [13] and rat model of diabetes [14]
compared with their respective non-diabetic controls.
In each of these models there is a wide range of
fractional beta cell areas in the non-diabetic controls [3,
13, 14]. It is conceivable that this is due to variation in
pancreas volume [15]. However, a wide range of beta cell
masses in non-diabetic humans has also been reported
[16].
Alternatively, the wide range in fractional beta call areas
in non-diabetic individuals represents adaptation to insulin
sensitivity. However, this seems unlikely, at least in
humans, as in morbidly obese humans the adaptive increase
in beta cell mass is only ∼50% compared with that in lean
individuals [2, 16–18]. Another possible explanation is that
maternal nutrition [19], placental function and both nutri-
tion and genetic regulation during postnatal expansion of
beta cell mass may define the adult beta cell mass [20].
The relationship between fractional beta cell area and the
fasting blood glucose concentration in adult STZ-treated
monkeys reported here is also comparable with that in
models of type 2 diabetes in adult rats [14] and pigs [13]. In
these models, once the fractional beta cell area is decreased
by approximately 50% or more of that in non-diabetic
individuals, glycaemic control is lost. After a loss of 50%
of beta cells in each of these models, there is steep rise in
fasting blood glucose concentration with each further
decrement in beta cell area. This curvilinear relationship
reported in adult rodents, pigs and now non-human
primates reproduces that previously observed in humans
[3]. Moreover, a similar relationship has recently been
reported in humans with pancreatitis [21].
The mechanisms responsible for the loss of regulation of
glycaemic control after a decrease in pancreatic beta cell area
of 50% or more is unknown. One plausible explanation is
that with declining beta cell mass the immediately secretable
insulin pool [22] is depleted leading to an impaired insulin
pulse mass, as previously documented after 50% pancrea-
tectomy [6]. Since the pattern of insulin delivery to the liver
influences insulin sensitivity [23, 24], we postulate that
once the immediately secretable insulin pool is depleted,
impaired pulsatile insulin leads to insulin resistance that
further confounds the defect in insulin secretion. Once
hyperglycaemia develops, the additional confounding ad-
verse effects of hyperglycaemia on beta cell function and
insulin sensitivity presumably contribute to the further
declining glycaemic control.
In conclusion, in adult non-human primates, a decline of
approximately 50% or more in pancreatic beta cells leads to
loss of glycaemic control with a relationship comparable
with that in adult humans. The cynomolgus monkey treated
with sufficient STZ to induce this deficit in beta cells is
therefore a useful model for type 2 diabetes.
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